Effect of Yinzhihuang oral liquid on neonatal hyperbilirubinemia
茵栀黄口服液治疗新生儿高胆红素血症的效果

摘要

目的 探讨茵栀黄口服液应用在新生儿高胆红素血症的临床价值。方法 对我院2020年3月-2021年5月收治的72例新生儿高胆红素血症作为此次研究病例，按照随机数字表法分组，研究组和参照组各36例，参照组用蓝光治疗，研究组在参照组基础上加用茵栀黄口服液，比较两组的临床效果与不良反应发生率，并评估两组治疗后第1/2/3/4/5/6天总胆红素含量、直接胆红素含量。结果 研究组临床有效率（91.67%）高于参照组（69.44%），与参照比较，研究组每日粪便中总胆红素含量多，直接胆红素含量多，研究组不良反应发生率（5.56%）低于参照组（27.78%），研究组的PDI、MDI水平低于参照组，差异呈P<0.05。结论 茵栀黄口服液治疗新生儿高胆红素血症的疗效确切，可改善患儿的总胆红素与直接胆红素含量水平，提高治疗效果，安全性高，值得推广应用。

Abstract

Objective To explore the clinical value of Yinzhihuang oral liquid in the treatment of neonatal hyperbilirubinemia.
Methods 72 cases of neonatal hyperbilirubinemia admitted to our hospital from March 2020 to May 2021 were selected as the study cases. They were randomly divided into two groups according to the number table method. The study group and the reference group each had 36 cases, and the reference group were treated with blue light. The study group added Yinzhihuang oral liquid to the reference group, and compared the clinical effects and adverse reaction rates of the two groups. The total bilirubin content and direct bilirubin content of the two groups on the 1st/2nd/3rd/5th/6th day after treatment were evaluated.
Results The clinical effective rate of the study group (91.67%) was higher than that of the reference group (69.44%). Compared with the reference group, the daily total bilirubin content in the feces of the study group was higher, and the direct bilirubin content was higher. The incidence of adverse reactions in the study group (5.56%) was lower than that of the reference group (27.78%). The levels of PDI and MDI in the study group were lower than that of the reference group, with a difference of P<0.05.
Conclusion   Yinzhihuang oral liquid is effective in the treatment of neonatal hyperbilirubinemia, can improve the levels of total bilirubin and direct bilirubin in children, improve the treatment effect, and has high safety. It is worth promoting and applying.